
Newsletter
Promoter: | pennyomega.com | Paying Party: | No Third Party |
Stocks covered: | Compensation: | Avg $ Volume for Period: |
ASTM | Unknown compensation | UNKNOWN |
Max Profit: Pending | Gain at close: Pending | |
*We think that this promoter is a part of a group of promoters. | ||
CMTL | Unknown compensation | UNKNOWN |
Max Profit: Pending | Gain at close: Pending | |
*We think that this promoter is a part of a group of promoters. |

Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading developer of expanded autologous cellular therapies for the treatment of severe, chronic cardiovascular diseases, announced that it has completed a public offering of 10,000,000 units at a price to the public of $2.25 per unit for an aggregate offering amount of $22.5 million, as previously announced on December 10, 2010. The net proceeds to Aastrom, after underwriting discounts and commissions and other offering expenses, from the sale of the units are approximately $20.5 million. The Company intends to use the net proceeds from the offering for general corporate purposes, including research and development expenses such as expenses related to its Phase 3 CLI program, capital expenditures, working capital and general administrative expenses.
Stifel Nicolaus Weisel acted as sole book-running manager and Needham & Company, LLC and Roth Capital Partners acted as co-managers.
The offering was made to purchasers pursuant to an effective shelf registration statement that Aastrom filed with the Securities and Exchange Commission, or the SEC, on November 12, 2010. A final prospectus supplement relating to the offering was filed with the SEC on December 10, 2010.
Aastrom Biosciences is an emerging biotechnology company developing expanded autologous cellular therapies for use in the treatment of severe, chronic cardiovascular diseases. The company's proprietary cell-processing technology enables the manufacture of mixed-cell therapies expanded from a patient's own bone marrow and delivered directly to damaged tissues. Aastrom has advanced its cell therapies into late-stage clinical development, including a planned Phase 3 clinical program for the treatment of patients with critical limb ischemia and two ongoing Phase 2 clinical trials in patients with dilated cardiomyopathy.
Comtech Telecommunications Corp. (Nasdaq:CMTL) announced that its Tempe, Arizona-based subsidiary, Comtech EF Data Corp., obtained a $1.0 million order for modems, the Vipersat Management System (VMS) and performance enhancement proxies. The equipment will support a Vipersat-powered network for a United States government agency. Initially, it will connect a hub to 32 remote sites to facilitate voice and data services.
The SLM-5650A Satellite Modem was specified in the order, which is MIL-STD-188-165A modem types I, II, IV, V and VI compliant. When configured with the Network Processor module, it provides a wide variety of advanced Internet Protocol (IP) features including routing, switching, Quality of Service, and Vipersat dynamic bandwidth control. The demodulator-only version of the SLM-5650A Satellite Modem was also ordered, the SLM-5650AD.
The VMS provides dynamic Single Carrier per Channel (dSCPC) bandwidth management of the space segment. When integrated with the SLM-5650A Satellite Modem, the dSCPC technology provides the mechanism to automatically establish the high-speed IP SCPC carrier when a remote has an application to transport over the satellite link.
Also included in the order was the turboIP®-G2 Performance Enhancement Proxy, which combats the inherent challenges of transmitting TCP over satellite links. Transparently accelerating TCP sessions at speeds of 15 or 45 Mbps, the turboIP®-G2 increases throughput over satellite links while requiring minimal topology changes.
Comtech Telecommunications Corp. designs, develops, produces and markets innovative products, systems and services for advanced communications solutions. The Company believes many of its solutions play a vital role in providing or enhancing communication capabilities when terrestrial communications infrastructure is unavailable, inefficient or too expensive.
**************************************************************
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. PennyOmega.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold PennyOmega.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://pennyomega.com/disclaimer) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.